Clinical trials: Major Depressive Disorder, completed
Depression
Riluzole to Treat Major Depression
This study will examine the safety and effectiveness of the drug riluzole (Rilutek® (Registered Trademark)) for short-term treatment of depression symptoms, such as depressed mood, psychomotor retardation, and excessive sleeping.
- Trial name
- NCT00026052
- Testing
- riluzole
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)
Post-Traumatic Stress Disorders, Healthy
Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder
The purpose of this study is to determine whether people who develop Post-Traumatic Stress Disorder (PTSD) after a trauma have increased sensitivity to the effects of a stress hormone.
- Trial name
- NCT00039715
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Clinical Trial of Memantine for Major Depression
The purpose of this study is to determine the safety and effectiveness of the drug memantine for treating major depression. Major depression is a serious public health concern that contributes to significant morbidity and…
- Trial name
- NCT00040261
- Testing
- Memantine HCL
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Examination of a Soy-Based Supplement for Major Depression
The purpose of this study is to find out if the soy-based dietary supplement Novasoy (Registered Trademark) is effective for the short-term treatment of clinical depression.
- Trial name
- NCT00042380
- Testing
- Novasoy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.
- Trial name
- NCT00285376
- Testing
- vilazodone
- Where
- 15 sites in United States
- Volunteers
- 410 people
- Sponsor
- Genaissance Pharmaceuticals
Depressive Disorder
Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy
Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.
- Trial name
- NCT00618865
- Testing
- Omega-3 fatty acids
- Volunteers
- 36 people
- Sponsor
- National Science and Technology Council, Taiwan
Major Depressive Disorder
Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder
Assessing psychiatric and physiological co-morbidity in TRD and non-TRD patients
- Trial name
- NCT00229398
- Sponsor
- Sheba Medical Center
Major Depression
PUFA Augmentation in Treatment of Major Depression
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder.
- Trial name
- NCT00067301
- Testing
- Polyunsaturated Fatty Acids (PUFA), Citalopram
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Atypical Depression
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression
This is a Pilot Study to get a first indication whether Duloxetine may be effective for depressed patients with Atypical Features.
- Trial name
- NCT00296699
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have an inadequate response (partial or non-responder) will be randomized to receive either mecamylamine (5-10mg) or placebo added to their…
- Trial name
- NCT00593879
- Testing
- Mecamylamine
- Volunteers
- 450 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients
- Trial name
- NCT00384436
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 580 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
- Trial name
- NCT00277823
- Testing
- DVS-SR 50 mg, DVS-SR 100 mg
- Where
- 25 sites in United States
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Fibromyalgia, Posttraumatic Stress Disorder
Fibromyalgia in Men Suffering From PTSD
Assessing FM and psychiatric state among PTSD, MDD and healthy participants
- Conditions
- Fibromyalgia, Posttraumatic Stress Disorder, Major Depressive Disorder
- Trial name
- NCT00229294
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Depression
Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Trial name
- NCT00329147
- Testing
- desvenlafaxine SR, desipramine, paroxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Bipolar Disorder
Behavioral Processes Underlying Reward Processing in Depression
The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.
- Trial name
- NCT00205933
- Where
- 2 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Affective Neuroscience Laboratory
Major Depressive Disorder
The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity
The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.
- Trial name
- NCT00205946
- Testing
- Bupropion
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Affective Neuroscience Laboratory
Depressive Disorder, Major
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder.
- Trial name
- NCT00300378
- Testing
- desvenlafaxine 50 mg, desvenlafaxine 100 mg
- Where
- 43 sites in Croatia, Estonia and 8 more
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer